Skip to main content
SpringerLink
Log in

Antiplatelet Therapy. New Potent P2Y12 Inhibitors

  • Chapter
  • First Online:
Pharmacological Treatment of Acute Coronary Syndromes

Part of the book series: Current Cardiovascular Therapy ((CCT))

  • 1472 Accesses

Abstract

Atherosclerosis is a chronic inflammatory process known to be the underlying cause of coronary artery disease. Platelets play an important role in the thrombotic process that follows rupture, fissure, or erosion of an atherosclerotic plaque. Atherothrombotic events are essentially platelet-driven processes and this underscores the role of antiplatelet agents as the cornerstone treatment for patients with acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI). Platelet P2Y12 receptor antagonism with ticlopidine and later clopidogrel has represented a major advance in the pharmacological management of patients with atherothrombotic disease. Despite the benefit associated with clopidogrel therapy in these high risk settings, a considerable number of adverse events continue to occur with this dual antiplatelet therapy regimen. The aim of this chapter is to provide an overview on the current status of antiplatelet agents, specifically the new potent P2Y12 inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 49.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938–49.

    Article  PubMed  CAS  Google Scholar 

  2. Ferreiro JL, Angiolillo DJ. New directions in antiplatelet therapy. Circ Cardiovasc Interv. 2012;5(3):433–45.

    Article  PubMed  Google Scholar 

  3. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287.

    Article  PubMed  CAS  Google Scholar 

  4. Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001;107:1591.

    Article  PubMed  CAS  Google Scholar 

  5. Kristensen SD, Würtz M, Grove EL, De Caterina R, Huber K, Moliterno DJ, Neumann FJ. Contemporary use of glycoprotein IIb/IIIa inhibitors. Thromb Haemost. 2012;107(2):215–24.

    Article  PubMed  CAS  Google Scholar 

  6. Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012;72(16):2087–116.

    Article  PubMed  CAS  Google Scholar 

  7. May JA, Heptinstall S, Cole AT, Hawkey CJ. Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. Thromb Res. 1997;88:183–92.

    Article  PubMed  CAS  Google Scholar 

  8. Perneby C, Wallén NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost. 2006;95:652–8.

    PubMed  CAS  Google Scholar 

  9. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–83.

    Article  PubMed  CAS  Google Scholar 

  10. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (part 1). N Engl J Med. 1992;326:242–50.

    Article  PubMed  CAS  Google Scholar 

  11. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol. 1988;12:3A–13.

    Article  Google Scholar 

  12. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.

    Article  Google Scholar 

  13. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van’t Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619.

    Article  PubMed  CAS  Google Scholar 

  14. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054.

    Article  PubMed  Google Scholar 

  15. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets. 2001;12:443–7.

    Article  PubMed  CAS  Google Scholar 

  16. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs. 1995;49:856–84.

    Article  PubMed  CAS  Google Scholar 

  17. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505–16.

    Article  PubMed  CAS  Google Scholar 

  18. Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb Haemost. 2009;102:7–14.

    PubMed  CAS  Google Scholar 

  19. CAPRIE SteeringCommittee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39.

    Article  Google Scholar 

  20. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.

    Article  PubMed  CAS  Google Scholar 

  21. Sabatine MS, Cannon CP, CLARITY-TIMI 28 Investigators, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–89.

    Article  PubMed  CAS  Google Scholar 

  22. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–21.

    Article  PubMed  CAS  Google Scholar 

  23. Steinhubl SR, Berger PB, CREDO Investigators, et al. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–20.

    Article  PubMed  CAS  Google Scholar 

  24. Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators: clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.

    Article  PubMed  CAS  Google Scholar 

  25. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation. 2010;122:394–403.

    Article  PubMed  Google Scholar 

  26. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119(19):2553–60.

    Article  PubMed  CAS  Google Scholar 

  27. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.

    Article  PubMed  CAS  Google Scholar 

  28. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for STelevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723–31.

    Article  PubMed  CAS  Google Scholar 

  29. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626–36.

    Article  PubMed  CAS  Google Scholar 

  30. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM, TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297–309.

    Article  PubMed  CAS  Google Scholar 

  31. Htun WW, Steinhubl SR. Ticagrelor: the first novel reversible P2Y12 inhibitor. Expert Opin Pharmacother. 2013;14(2):237–45.

    Article  PubMed  CAS  Google Scholar 

  32. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–85.

    Article  PubMed  CAS  Google Scholar 

  33. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

    Article  PubMed  CAS  Google Scholar 

  34. James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA, PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011;342:d3527.

    Article  PubMed  Google Scholar 

  35. Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanu-elsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L, PLATelet Inhibition and Patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375:283–93.

    Article  PubMed  CAS  Google Scholar 

  36. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhi- bition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672–84.

    Article  PubMed  CAS  Google Scholar 

  37. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122:1056–67.

    Article  PubMed  Google Scholar 

  38. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L, PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544–54.

    Article  PubMed  CAS  Google Scholar 

  39. Wallentin L, Becker RC, James SK, Harrington RA. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Thromb Haemost. 2011;105:760–2.

    Article  PubMed  CAS  Google Scholar 

  40. Tan GM, Lam YY, Yan BP. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome. Cardiovasc Ther. 2012;30(4):e167–73.

    Article  PubMed  CAS  Google Scholar 

  41. Wang K, Zhou X, Zhou Z, et al. Sustained coronary artery recanalization with adjunctive infusion of a novel P2T-receptor antagonist AR-C69931 in a canine model. J Am Coll Cardiol. 2000;35(suppl):281A–2.

    Google Scholar 

  42. Akers WS, Oh JJ, Oestreich JH, Ferraris S, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50:27–35.

    Article  PubMed  CAS  Google Scholar 

  43. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack Jr CV, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361:2318–29.

    Article  PubMed  CAS  Google Scholar 

  44. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack Jr CV, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA, CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361:2330–41.

    Article  PubMed  CAS  Google Scholar 

  45. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA, CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303–13.

    Article  PubMed  CAS  Google Scholar 

  46. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T, Montalescot G, Manoukian SV, Prats J, Topol EJ. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307:265–74.

    Article  PubMed  CAS  Google Scholar 

  47. Gretler DD, Conley PB, Andre P, et al. “First in human” experience with PRT060128, a new directacting, reversible, P2Y12 inhibitor for IV and oral use. J Am Coll Cardiol. 2007;9 Suppl 2:326A.

    Google Scholar 

  48. Gurbel PA, Bliden KP, Antonino MJ, et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost. 2010;8:43–53.

    Article  PubMed  CAS  Google Scholar 

  49. Müller KA, Geisler T, Gawaz M. Elinogrel, an orally and intravenously available ADP-receptor antagonist. How does elinogrel affect a personalized antiplatelet therapy? Hamostaseologie. 2012;32(3):191–4.

    Article  PubMed  Google Scholar 

  50. Berger JS, Roe MT, Gibson CM, Kilaru R, Green CL, Melton L, Blankenship JD, Metzger DC, Granger CB, Gretler DD, Grines CL, Huber K, Zeymer U, Buszman P, Harrington RA, Armstrong PW. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J. 2009;158(6):998–1004.

    Article  PubMed  CAS  Google Scholar 

  51. Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA, INNOVATE-PCI Investigators. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012;5(3):336–46.

    Article  PubMed  CAS  Google Scholar 

  52. Zhao L, Bath PM, Fox S, May J, Judge H, Lösche W, Heptinstall S. The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. Curr Med Res Opin. 2003;19:178–86.

    Article  PubMed  CAS  Google Scholar 

  53. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, Heeschen C, Hamm CW, Robbins MA, Kleiman NS, Théroux P, White HD, White HD, Topol EJ. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J. 2002;23:1441–8.

    Article  PubMed  CAS  Google Scholar 

  54. Angiolillo DJ, Ueno M. Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations. J Am Coll Cardiol Cardiovasc Interv. 2011;4:411–4.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain

    Pablo Avanzas MD, PhD, FESC

  2. Department of Cardiology, Universidad de Oviedo, Oviedo, Spain

    Cesar Morís MD, PhD

  3. Department of Cardiology, The Heart Center, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark

    Peter Clemmensen MD, PhD, FESC

Authors
  1. Pablo Avanzas MD, PhD, FESC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cesar Morís MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Clemmensen MD, PhD, FESC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pablo Avanzas MD, PhD, FESC .

Editor information

Editors and Affiliations

  1. Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Spain

    Pablo Avanzas

  2. Department of Cardiology, The Heart Center, Rigshospitalet University Hospital of Copenhagen,, Copenhagen, Denmark

    Peter Clemmensen

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Avanzas, P., Morís, C., Clemmensen, P. (2014). Antiplatelet Therapy. New Potent P2Y12 Inhibitors. In: Avanzas, P., Clemmensen, P. (eds) Pharmacological Treatment of Acute Coronary Syndromes. Current Cardiovascular Therapy. Springer, London. https://doi.org/10.1007/978-1-4471-5424-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-5424-2_2

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-5423-5

  • Online ISBN: 978-1-4471-5424-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation